Drug · CHEMBL6068614

PROTHROMBIN COMPLEX CONCENTRATE

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. PROTHROMBIN COMPLEX CONCENTRATE. Drugs and targets, record CHEMBL6068614. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL6068614

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: PROTHROMBIN COMPLEX CONCENTRATE; ChEMBL
ChEMBL ID: CHEMBL6068614; ChEMBL
Type: Protein; ChEMBL
Other names: Kcentra, Octaplex 500 iu; ChEMBL
Open Targets' highest stage: Approval, as Open Targets' drug record gives it; Open Targets

Targets6

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
F10	Coagulation factor X	Coagulation factor X exogenous protein	EXOGENOUS PROTEIN	https://conductscience.org/library/genes/2159
F2	Prothrombin	Thrombin exogenous protein	EXOGENOUS PROTEIN	https://conductscience.org/library/genes/2147
F7	Coagulation factor VII	Coagulation factor VII exogenous protein	EXOGENOUS PROTEIN	https://conductscience.org/library/genes/2155
F9	Coagulation factor IX	Coagulation factor IX exogenous protein	EXOGENOUS PROTEIN	https://conductscience.org/library/genes/2158
PROC	Vitamin K-dependent protein C	Vitamin K-dependent protein C exogenous protein	EXOGENOUS PROTEIN	https://conductscience.org/library/genes/5624
PROS1	Vitamin K-dependent protein S	Vitamin K-dependent protein S exogenous protein	EXOGENOUS PROTEIN	https://conductscience.org/library/genes/5627

Source ChEMBL

Diseases9

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
hemorrhage	Phase 3	ClinicalTrials.gov	5	5	https://conductscience.org/library/drugs?q=MP_0001914
blood coagulation disease	Phase 3	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0001531
Multiple Organ Failure	Phase 3	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=EFO_1001373
cardiac transplant	Phase 3	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=EFO_0010673
coagulation protein disease	Phase 3	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0002242
factor VII deficiency	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0002244
injury	Phase 3	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=MONDO_0021178
intracranial hemorrhage	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=EFO_0000551
postpartum hemorrhage	Unknown	ClinicalTrials.gov	1	1	https://conductscience.org/library/drugs?q=EFO_0009579

Source Open Targets

Trials37

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 6 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT05523297	Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery	Phase 3	420	2025-08-15	prothrombin complex concentrate	Its name	ClinicalTrials.gov
NCT00708435	Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy	Phase 3	216	2013-08-13	prothrombin complex concentrate	Its name	ClinicalTrials.gov
NCT02740335	Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.	Phase 3	208	2023-03-08	octaplex, prothrombin complex concentrate	Its name	ClinicalTrials.gov
NCT02557672	PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding	Phase 4	106	2022-06-07	prothrombin complex concentrate	Its name	ClinicalTrials.gov
NCT03064035	Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal	Phase 4	79	2023-07-11	prothrombin complex concentrate	Its name	ClinicalTrials.gov
NCT02074358	A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects	Phase 1	43	2015-08-13	beriplex p/n	Open Targets' reading, confirmed by the trial's result groups	ClinicalTrials.gov
NCT06627218	Liberal or Adhere to Recommendations for PCC Management in Major Bleeding Following Trauma		650		prothrombin complex concentrate	Its name	ClinicalTrials.gov
NCT04244981	Efficacy of Prothrombin Complex Concentrate Reducing Perioperative Blood Loss in Cardiac Surgery	Phase 4	476		prothrombin complex concentrate	Its name	ClinicalTrials.gov
NCT05667805	Coagulation in Cirrhosis	Phase 4	400		prothrombin complex concentrate	Its name	ClinicalTrials.gov
NCT01961804	PREVACT : Preventive REversal of Vitamine K Antagonist in Minor Craniocerebral Trauma	Phase 3	202		prothrombin complex concentrate	Its name	ClinicalTrials.gov

1 to 10 of 37

See all 37 trials

Comparisons in its trials14

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Octaplex vs Frozen Plasma: Comparison of the Incidence of Death Between Octaplex and FP Groups	7 of 213	8 of 207	420	NCT05523297	Trial comparisons
Octaplex vs Frozen Plasma: Comparison of Incidence of Serious Treatment-emergent Adverse Events Between Octaplex and FP Groups	77 of 213	98 of 207	420	NCT05523297	Trial comparisons
Octaplex vs Frozen Plasma: deaths from any cause	7 of 213	8 of 207	420	NCT05523297	Trial comparisons
Octaplex vs Frozen Plasma: serious adverse events	77 of 213	98 of 207	420	NCT05523297	Trial comparisons
Beriplex® P/N vs Fresh Frozen Plasma: serious adverse events	32 of 103	26 of 109	212	NCT00708435	Trial comparisons
Octaplex vs Beriplex P/N (Kcentra): deaths from any cause	5 of 105	1 of 103	208	NCT02740335	Trial comparisons
Octaplex vs Beriplex P/N (Kcentra): serious adverse events	13 of 105	6 of 103	208	NCT02740335	Trial comparisons
Beriplex® P/N vs Fresh Frozen Plasma: 45-Day All-cause Mortality	9 of 98	5 of 104	202	NCT00708435	Trial comparisons
Fresh Frozen Plasma vs Prothrombin Complex Concentrate: deaths from any cause	2 of 49	1 of 51	100	NCT02557672	Trial comparisons
Fresh Frozen Plasma vs Prothrombin Complex Concentrate: serious adverse events	44 of 49	45 of 51	100	NCT02557672	Trial comparisons

1 to 10 of 14

See all 14 comparisons in its trials

Papers from its trials24

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
27302126	RESULT	1	PubMed
27170068	RESULT	1	PubMed
26591047	RESULT	1	PubMed
23935011	RESULT	1	PubMed
22356641	RESULT	1	PubMed
21158750	RESULT	1	PubMed
19787352	RESULT	1	PubMed
18208533	RESULT	1	PubMed
42404094	DERIVED	1	PubMed
40982282	DERIVED	1	PubMed

1 to 10 of 24

See all 24 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL6068614

GET https://conductscience.org/api/drugs/v1/CHEMBL6068614/trials?page=2

API reference For AI assistants